The GSTM1 Knockout MDA-MB-231 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal cell population in which the human GSTM1 gene has been disrupted, generating a loss-of-function model for glutathione S-transferase mu 1 (GSTM1). This knockout format yields a heterogeneous pool of edited cells, suitable for studying gene function without clonal isolation, enabling researchers to investigate the collective impact of GSTM1 ablation on cellular physiology. The model is derived from the MDA-MB-231 breast adenocarcinoma cell line, a widely utilized system for exploring triple-negative breast cancer (TNBC) biology. The polyclonal nature allows for robust assessment of GSTM1-dependent phenotypes in a population context, reflecting the complexity of tumor heterogeneity in experimental settings.
The host cell line, MDA-MB-231, was originally isolated from the pleural effusion of a metastatic breast adenocarcinoma patient and exhibits an epithelial origin with pronounced mesenchymal characteristics. These cells are triple-negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), representing an aggressive and invasive breast cancer subtype. The mesenchymal features contribute to enhanced migratory and invasive capacity, making this model particularly relevant for studying metastatic progression and therapy resistance. The cell line’s genetic background, including mutations in TP53 and KRAS, further complements the investigation of stress response and survival pathways.
GSTM1 encodes a phase II detoxification enzyme that catalyzes the conjugation of reduced glutathione (GSH) to a broad spectrum of electrophilic compounds, including xenobiotics, carcinogens, and oxidative stress byproducts. This reaction facilitates the elimination of toxic metabolites and protects cells from DNA adduct formation and lipid peroxidation. Beyond its catalytic role, GSTM1 acts as an endogenous inhibitor of apoptosis signal-regulating kinase 1 (ASK1) by direct protein-protein interaction; GSTM1 binding suppresses ASK1-mediated activation of the JNK and p38 MAPK pathways. Upstream, GSTM1 expression is regulated by transcription factors such as NRF2 via the antioxidant response element, as well as by AhR and HIF1A, linking its expression to oxidative and xenobiotic stress sensing. Downstream, GSTM1 knockout derepresses ASK1, promoting phosphorylation of JNK and p38, which can lead to stress-induced apoptosis and ferroptosis, and abolishes glutathione conjugation capacity, resulting in elevated reactive oxygen species (ROS) and electrophilic burden.
In the MDA-MB-231 context, GSTM1 disruption takes on particular significance due to the cell line’s basal ROS levels and its reliance on adaptive stress responses. TNBC cells often exhibit elevated oxidative stress and dysregulated redox signaling, partly compensated by upregulated detoxification systems. Loss of GSTM1 function in this invasive model is expected to potentiate oxidative damage, enhance susceptibility to ferroptotic stimuli, and alter the MAPK signaling equilibrium, potentially impacting proliferation, migration, and chemosensitivity. This knockout system thus enables dissection of GSTM1’s role in maintaining redox homeostasis and modulating cell death decisions in a clinically challenging breast cancer subtype.
Researchers can employ this product in a wide range of applications, including investigation of oxidative stress responses, chemosensitization screening, ferroptosis mechanisms, drug metabolism profiling, and MAPK pathway analysis. Compatible assays include western blotting for GSTM1, ASK1, phospho-JNK, and phospho-p38; glutathione S-transferase activity measurements; ROS detection with DCFDA; MTT viability and Annexin V/PI apoptosis assays; ferroptosis marker analysis (GPX4, lipid peroxidation); and co-immunoprecipitation of GSTM1-ASK1 complexes. The polyclonal format is well-suited for pharmacological studies testing GST inhibitors or redox-modulating agents, providing a physiologically relevant platform for discovery and validation of therapeutic targets. For further information, please contact Ascent Research.
